There is no fee for this educational activity.

---

Panelists/Lectures

“Understanding The Impact Of MRSA In The Diabetic Foot”

David G. Armstrong, DPM, PhD- Chairman/Moderator
Professor of Surgery, Chair of Research and Assistant Dean
William M. Scholl College of Podiatric Medicine
Rosalind Franklin University of Medicine
Chicago

“How To Differentiate Between CA-MRSA And HA-MRSA”

Benjamin Lipsky, MD
Professor of Medicine
University Of Washington School Of Medicine
Director, General Internal Medicine Clinic
Head, Antibiotic Research Clinic
VA Puget Sound Health Care System
Seattle

“A Review Of Current And Emerging Agents For MRSA”

Warren Joseph, DPM, FIDSA
Consultant, Lower Extremity Infectious Diseases
Fellow, Infectious Diseases Society of America
Attending Podiatrist, Coatesville Veterans Affairs Medical Center
Coatesville, Pa.

 

Target Audience
This activity is for podiatrists, infectious disease physicians, general surgeons, vascular surgeons and orthopedic surgeons.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• cite current statistics on the prevalence of MRSA

• discuss the potential impact of MRSA in diabetic foot infections and related complications

• review key risk factors for developing healthcare-associated MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA)

• compare and contrast the characteristics of HA-MRSA and CA-MRSA

• discuss guidelines from the Infectious Diseases Society Of America (IDSA) as they relate to diagnosing diabetic foot infections and appropriate culturing practices

• review the importance of appropriate antibiotic selection and how it can help reduce the potential for antibiotic resistant strains

• compare the currently available anti-MRSA agents in regard to efficacy and safety

• review new research on emerging cephalosporin and glycopeptide agents with anti-MRSA activity
         
Support/Sponsorship

This activity is supported by an educational grant from Pfizer.
This activity is sponsored by the North American Center For Continuing Medical Education (NACCME).

Accreditation

MD/DO:
This activity is sponsored by the North American Center for Continuing Medical Education (NACCME). NACCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies.

Podiatrists:

NACCME is approved by the Council on Podiatric Medical Education as a sponsor of continuing education in podiatric medicine. This program is approved for 1 continuing education contact hour.

Disclosures

Dr. Armstrong has disclosed that he has no significant financial relationship with any organization that could be perceived as a conflict of interest in the context of his article.

Dr. Lipsky has disclosed that he has received grant/research support from Merck, Johnson & Johnson and Pfizer. He is a consultant for Cubist, Pfizer and Wyeth. He is a scientific advisor for Merck and Pfizer. He is a member of the speakers’ bureau for Merck and Pfizer.

Dr. Joseph has disclosed that he is a consultant for Pfizer and is a member of the speakers’ bureau for Pfizer and Merck.